Vaginal Hydrogel with Thiol Crosslinking for pH-Matched Drug Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for vaginitis, such as intravaginal creams and systemic oral medications, face issues like messiness, reduced efficacy due to drug loss through vaginal secretions, pH imbalances, and side effects from systemic treatments, which do not effectively address vaginal dryness, infection, and inflammation simultaneously, especially since they are not formulated at the optimal pH of 3.2-5.0 for the vaginal environment.
Innovation Solution
Development of hydrogels with a pH between 3.2 and 5.0, incorporating glycosaminoglycans with thiol groups and thiol-reactive sites, and mucoadhesive agents like methylcellulose, which are covalently or ionically crosslinked to provide moisture and deliver therapeutic agents like antibacterial and anti-inflammatory agents, maintaining stability and efficacy within the vaginal environment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intravaginal creams and gels are used to treat vaginitis, then the drug delivery is improved, but the messiness and drug loss through vaginal secretions worsen
Solution Approach 1:
The patent changes the pH parameter of the hydrogel formulation to match the vaginal environment (pH 3.2-5.0), which improves drug stability and reduces drug loss through vaginal secretions while maintaining delivery efficacy
Solution Approach 2:
The patent uses composite hydrogel materials incorporating glycosaminoglycans with thiol groups and thiol-reactive sites that form crosslinked networks, creating a matrix that reduces drug loss through vaginal secretions while maintaining delivery effectiveness
2Adaptability or versatility
If systemic oral treatments are used to treat vaginitis, then the treatment coverage is improved, but the side effects worsen
Solution Approach 1:
The patent delivers therapeutic agents locally via vaginal hydrogel administration, concentrating the drug action at the site of infection (vagina) rather than systemically, which treats the condition effectively while minimizing side effects throughout the body
Solution Approach 2:
The hydrogel acts as an intermediary carrier that delivers therapeutic agents directly to the vaginal tissue, enabling localized treatment without the need for systemic absorption and associated side effects
3Stability of the object's composition
If hydrogels are formulated at standard physiological pH (7.4), then the hydrogel stability is improved, but the vaginal environment compatibility worsens
Solution Approach 1:
The patent adjusts the pH parameter of the hydrogel formulation from standard physiological pH (7.4) to match the vaginal environment (pH 3.2-5.0), which maintains hydrogel stability while ensuring compatibility with the vaginal microflora and preventing pH imbalance
Solution Approach 2:
The patent formulates the hydrogel with locally appropriate pH characteristics (pH 3.2-5.0) that match the vaginal environment, creating a formulation that is both stable and compatible with the specific biological conditions of the vagina
4Reliability
If current treatments are used to address vaginal dryness, infection, or inflammation, then the specific symptom treatment is improved, but the simultaneous treatment of multiple aspects worsens
Solution Approach 1:
The patent creates a multi-functional hydrogel formulation that simultaneously addresses vaginal dryness, infection, and inflammation by incorporating multiple therapeutic agents and moisture-retaining components in a single product, eliminating the need for separate treatments for each condition
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The hydrogels effectively treat vaginal dryness, infection, and inflammation while maintaining stability and delivering therapeutic agents, ensuring prolonged action and minimizing side effects by matching the vaginal pH, thus addressing the limitations of existing treatments.
Implementation Method 1
These hydrogels can be based on natural or synthetic materials, or a combination of the two. Typically, hydrogels will be crosslinked, either through physical interaction—such as simple entanglement, hydrogen bonding, or ionic interaction—or through covalent bonds.
Implementation Method 2
the average pH of the vagina is typically between about 3.2 and 5.0, an environment that favors microflora that are beneficial to the vagina. If the pH of the vagina is increased, a shift in the balance of the microflora occurs
Implementation Method 3
The composition includes a glycosaminoglycan which has thiol groups and a molecule that has at least 2 thiol-reactive sites
Data Source
AI summary
The vaginal hydrogel may be a composition which includes a glycosaminoglycan, a reactive molecule, and, in some embodiments, a therapeutic agent. The glycosaminoglycan and the reactive molecule may include either thiol groups or thiol reactive sites and have a pH that is within a range of a normal vaginal environment. Some of the thiol groups may interact with the vaginal mucosa and allow the hydrogel to remain in the vagina for a longer period than existing compounds intended for intravaginal administration. Therapeutic agents may be included in the composition. In these embodiments, the hydrogel acts as a vehicle which delivers the therapeutic agent.